Posted by Michael Wonder on 16 Jun 2018
ICER report questions the adequacy of evidence on overall health benefit of elagolix given limitations of information on safety and limited evidence comparing to other treatment options
15 June 2018 - The emerging drug may be cost-effective compared to no treatment if priced in line with analyst expectations, but large number of potentially eligible patients may pose short-term affordability challenges for health systems --
The ICER today released an evidence eeport assessing the comparative clinical effectiveness and value of elagolix (AbbVie/Neurocrine Biosciences) for the management of endometriosis and associated pain. Elagolix is currently under review by the FDA, with an approval decision expected in mid-2018.
This Evidence Report will be the subject of an upcoming public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) in Burlington, VT on 12 July 2018. The New England CEPAC is one of ICER's three independent evidence appraisal committees comprising medical evidence experts, practicing clinicians, methodologists, and leaders in patient engagement and advocacy. The Council will also review ICER's recently released condition update on treatments for plaque psoriasis during the meeting.
